TIBSOVO + azacitidine delivered a median overall survival of 24.0 months (95% CI, 11.3‑34.1)
vs 7.9 months (95% CI, 4.1‑11.3) with azacitidine (hazard ratio, 0.44; P<0.0010)1

47% of patients achieved CR on TIBSOVO + azacitidine
(95% CI, 35-59; P<0.0001) vs 15% on azacitidine (95% CI, 8-25)1
51% of patients achieved CR or CRh on TIBSOVO + azacitidine
(95% CI, 39-63; P<0.001) vs 18% on azacitidine (95% CI, 10-28)1
BOXED WARNING: Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal. TIBSOVO is associated with the following Warnings and Precautions: differentiation syndrome, QTc prolongation, and Guillain-Barré syndrome.1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend ivosidenib (TIBSOVO) + azacitidine as a category 1 preferred treatment option for newly diagnosed patients ≥60 years of age with mIDH1 who are not candidates for intensive remission induction therapy.3
Discover the importance of IDH1 testing at diagnosis and relapse
In newly diagnosed, IC‑ineligible AML
In
R/R AML

Choose TIBSOVO + azacitidine to maximize overall survival for your newly diagnosed, IC-ineligible mIDH1 patients1